Lupin To Gain At Ranbaxy's Expense?
  • Prabha Hedge
  • Feb 06 2014

February 6: Ranbaxy and Wockhardt's U.S. FDA troubles may spell good news for rival Lupin. Chief Executive Officer Vinita Gupta told Bloomberg that Lupin’s track record on quality and the overlap of drug portfolios with Indian rivals gives it an opportunity to add sales in the U.S. Bloomberg’s Ketaki Gokhale shares a detailed report on the same.